Novartis is still facing fallout from last year’s kickbacks case in South Korea. Officials there levied a set of punishments and are weighing "tougher…
The new WeGo Health Experts platform looks to fill a gap by allowing smaller healthcare companies a way to tap into the company’s large patient network.
Takeda has partnered with digital health tools venture Cognition Kit to collect active and passive patient data for a deep dive on depression.
Valeant’s executives did their darndest to point out the positives in the company’s Q4 earnings, but they couldn’t hide from the picture painted by the numbers.
The drug industry has built a unified wall of resistance to a pricing and transparency push in Maryland, the latest fight over state action against pricey meds.
After a late 2015 setback at the hands of the FDA, AstraZeneca is back with diabetes med Qtern—and ready to give rivals Lilly and BI some competition.
The pricing pressure that’s been tolling the generics industry has hit Endo—hard.
Astellas just forged a licensing deal with Affinivax to develop a pneumococcal vaccine. Their target? Pfizer’s Prevnar 13—the world’s best-selling vaccine.
J&J has joined fellow drug giant Pfizer and a half-dozen smaller drugmakers in a Justice Department probe of patient-assistance charities.
Floundering Perrigo’s CFO is hitting the road—along with hundreds of other employees, who didn’t have quite as much say in the matter.